 The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Incs NASDAQ: HCWB lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. HCW9218 is an injectable, bifunctional fusion protein complex designed to drive anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities. 